| The Wall Street Journal Western Edition 1999 Robert Langreth |
| Title | Subject | Authors |
|---|
| At J&J, a venerable strategy faces questions.(Johnson & Johnson faces questions about its business model)(Abstract) | Business, general | Robert Langreth, Ron Winslow |
| Bristol-Myers says net falls after charge.(Bristol-Myers Squibb Co.)(Abstract) | Business, general | Robert Langreth |
| Monsanto's arthritis drug, Celebrex, shows strong sales in its first week.(Abstract) | Business, general | Robert Langreth, Thomas M. Burton |
| Roche Holding's Xenical helps patients keep the weight off for up to 2 years.(Xenical is experimental )(Abstract) | Business, general | Robert Langreth |
| SmithKline is expected to sell two units; sale of pharmacy-benefits, clinical-lab businesses increases focus on drugs.(SmithKline Beecham PLC)(Abstract) | Business, general | Steven Lipin, Robert Langreth, Thomas M. Burton |
| Warner-Lambert's de Vink to succeed CEO Goodes, who is retiring early.(Lodewijk J.R. de Vink promoted to Melvin Goodes' post)(Who's News)(Abstract) | Business, general | Robert Langreth |
| Warner-Lambert's Rezulin sales could suffer.(sales of drug for diabetes could suffer )(Abstract) | Business, general | Robert Langreth, Rochelle Sharpe |
| Zeneca sues Eli Lilly over Evista promotion.(Abstract) | Business, general | Robert Langreth, Thomas M. Burton, Frances A. McMorris |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
